
About Adial Pharmaceuticals
Adial Pharmaceuticals is a publicly listed company based in Charlottesville (United States) founded in 2010 by Bankole Johnson. Therapeutics for addiction treatment are developed by Adial Pharmaceuticals. Adial Pharmaceuticals has raised $7.7 million across 15 funding rounds from investors including Keystone Capital Partners, Coastlands Capital and Boxer Capital. The company has 7 employees. Adial Pharmaceuticals has completed 1 acquisition, including Azora Therapeutics. Adial Pharmaceuticals offers products and services including AD04. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is Adial Pharmaceuticals, Inc. Its competitors include Indivior, Braeburn and Amygdala Neurosciences; 2 of its 3 listed competitors have raised funding.
Company details
Adial Pharmaceuticals was founded in 2010 and is headquartered in Charlottesville, United States. Therapeutics for addiction disorders are developed, with a focus on genetically targeted drugs such as AD04 for alcohol use disorder. Adenosine analogues under the Purnovate platform are also pursued for inflammatory and neurotransmission-related conditions. Operations center on pharmaceutical research and development in the biotech sector.
- Net Profit-$7.98 M (USD)39.56as on Dec 31, 2025
- EBITDA-$7.8 M (USD)5.85as on Dec 31, 2025
- Total Equity Funding$7.7M (USD)
in 15 rounds
- Latest Funding Round$64M (USD), Post-IPO
Jun 2026
- InvestorsKeystone Capital Partners
& 3 more
- Employee Count7
- Investments & Acquisitions
Products & Services of Adial Pharmaceuticals
Adial Pharmaceuticals offers a comprehensive portfolio of products and services, including AD04.
Genetically targeted treatment for alcohol use disorder via serotonin receptor antagonism
Apps and channels of Adial Pharmaceuticals
its YouTube channel Adial Pharmaceuticals has 163 subscribers and 26 videos.
Videos from Adial Pharmaceuticals
The most watched videos on Adial Pharmaceuticals's YouTube channel, Adial Pharmaceuticals (163 subscribers). Click a video to play it here.
More on Adial Pharmaceuticals.
Funding Insights of Adial Pharmaceuticals
Adial Pharmaceuticals has successfully raised a total of $7.7M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $64 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.7M
- Total Rounds 15
- Last Round Post-IPO — $64M
- First Round $4.1M
(Mar 2011)
- Investors Count 4
Latest 10 of 15 funding rounds of Adial Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $64M | Post-IPO | – | Coastlands Capital | |
| Mar 2024 | $287,500 | Post-IPO | – | – | – |
| Jun 2023 | $52,500 | Post-IPO | – | – | – |
| Nov 2021 | $800,000 | Post-IPO | – | – | – |
| Jul 2021 | $5M | Post-IPO | – | – | – |
| Mar 2021 | $2.1M | Post-IPO | – | – | |
| Nov 2020 | $295,750 | Post-IPO | – | – | – |
| Sep 2020 | $500,000 | Post-IPO | – | – | – |
| Jun 2018 | $325,000 | Series A | – | – | – |
| Feb 2018 | $500,000 | Series A | – | – | – |
4 investors in total: 4 institutional.
Investors in Adial Pharmaceuticals
Adial Pharmaceuticals has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Keystone Capital Partners, Coastlands Capital and Boxer Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An investment firm based in New York is operated. | keystone-cp.com | New York, United States | ||
| coastlandscapital.com | ||||
| boxercap.com | ||||
| stonepinecap.com |
Investor details for Adial Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adial Pharmaceuticals
1 people are tracked at Adial Pharmaceuticals (1 in leadership); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Bankole Johnson | Founder | Leadership |
Complete people profiles for Adial Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Adial Pharmaceuticals
Adial Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ADIL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jul 2018
- Listed onNASDAQ: ADIL
- Listed entityAdial Pharmaceuticals, Inc
- Exchange sectorHealth technology
Investments & Acquisitions by Adial Pharmaceuticals
Adial Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Azora Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapies for autoinflammatory diseases are developed. | azoratherapeutics.com | Los Angeles, United States | 2019 | Jun 2026 | •••• |
Complete acquisition details for Adial Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Adial Pharmaceuticals
5 dated milestones of Adial Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Adial Pharmaceuticals is founded.
- Funding First funding round of $4.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $64.0M.
- Acquisition Acquires Azora Therapeutics.
Competitors of Adial Pharmaceuticals
Adial Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Indivior, Braeburn and Amygdala Neurosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | ||
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | Long-acting therapies for opioid addiction and chronic pain are developed. | ||
| amygns.com | 2015 | San Francisco, United States | $7.05M | Therapies for substance use disorders are developed by Amygdala Neurosciences. |
Detailed competitors of Adial Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Adial Pharmaceuticals
The website of Adial Pharmaceuticals (adial.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 26.1% vs previous month
Top companies in Neurology
3 companies that operate in the same segment as Adial Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adial Pharmaceuticals
Complete news archive for Adial Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adial Pharmaceuticals
Adial Pharmaceuticals was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Adial Pharmaceuticals is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Adial Pharmaceuticals is a funded company, having raised a total of $7.7M across 15 funding rounds to date. The company's 1st funding round was a Series A of $500K, raised on Mar 2011.
Adial Pharmaceuticals has 7 employees.
Adial Pharmaceuticals was founded in 2010 and is headquartered in Charlottesville, United States. Therapeutics for addiction disorders are developed, with a focus on genetically targeted drugs such as AD04 for alcohol use disorder. Adenosine analogues under the Purnovate platform are also pursued for inflammatory and neurotransmission-related conditions. Operations center on pharmaceutical research and development in the biotech sector.
Adial Pharmaceuticals's top competitors include Indivior, Amygdala Neurosciences and Braeburn.
Adial Pharmaceuticals offers AD04.
Yes, Adial Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ADIL.
Adial Pharmaceuticals has made 1 acquisition, including Azora Therapeutics.
Adial Pharmaceuticals has 4 investors. Key investors include Keystone Capital Partners, Coastlands Capital, Boxer Capital, and Stonepine.
Adial Pharmaceuticals operates through Adial Pharmaceuticals, Inc..
